Gilenya (Fingolimod HCl) Patent Expiration, LOE Window & CMS Spending
Gilenya (Fingolimod HCl) by Novartis: FDA Orange Book LOE 2032-09-30, 15 AB generics, $89.6M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N022527 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-09-30 |
| Orange Book Patents (*PED Extensions) | 3 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 15 |
| 2024 CMS Total Public Spend | $89.6M |
| 2024 Medicare Part D Spend | $53.7M |
| 2024 Medicaid Spend | $36.0M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 23.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.